Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial

IMPORTANCE: Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with tr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:JAMA Oncol
Huvudupphovsmän: Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Huovinen, Riikka, Jukkola-Vuorinen, Arja, Tanner, Minna, Kokko, Riitta, Ahlgren, Johan, Auvinen, Päivi, Lahdenperä, Outi, Kosonen, Sanna, Villman, Kenneth, Nyandoto, Paul, Nilsson, Greger, Poikonen-Saksela, Paula, Kataja, Vesa, Junnila, Jouni, Bono, Petri, Lindman, Henrik
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Medical Association 2017
Ämnen:
Original Investigation
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5824321/
https://ncbi.nlm.nih.gov/pubmed/28253390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.6120
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk